Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

@article{Minotti2004AnthracyclinesMA,
  title={Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity},
  author={Giorgio Minotti and Pierantonio Menna and Emanuela Salvatorelli and Gaetano Cairo and Luca Gianni},
  journal={Pharmacological Reviews},
  year={2004},
  volume={56},
  pages={185 - 229}
}
The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one hand, anthracyclines play an undisputed key role in the treatment of many neoplastic diseases; on the other hand, chronic administration of anthracyclines induces cardiomyopathy and congestive heart failure usually refractory to common medications. Second-generation analogs like epirubicin or idarubicin exhibit improvements in their therapeutic index, but the risk of… 
Role of anthracyclines in the era of targeted therapy
TLDR
In the current target therapy era in oncology, anthracyclines increase the antitumor effects in more than additive fashion, being excellent partners for other active agents like taxanes and trastuzumab.
New developments in anthracycline-induced cardiotoxicity.
TLDR
This review discusses recent developments in the molecular mechanisms underlying anthracycline-induced cardiotoxicity, focusing on controversial aspects and on recent data regarding analogues of the natural compounds, tumor-targeted formulations and cardioprotective agents.
Anthracyclines and mitochondria.
TLDR
The potential role of mitochondria in the molecular mechanisms underlying anthracycline anticancer activity as well as in the pathogenesis of anthrACYcline-induced cardiotoxicity is reviewed.
Anthracyclines as effective anticancer drugs
TLDR
Based on their crystal structures as well as molecular modelling, a more detailed mechanism of topoisomerase poisoning by these new anthracyclines has emerged and this review focuses on the most recent pharmacology and medicinal chemistry developments on the design and use of anthrACYclines.
CHRONIC ANTHRACYCLINE CARDIOTOXICITY: MOLECULAR AND FUNCTIONAL ALTERATIONS IN THE POST-TREATMENT FOLLOW UP
TLDR
It is very difficult to directly assess ANT-induced myocardial changes and their further development in the post-treatment period in clinical settings, and recent data suggest that mitochondria can be the main target of ANT toxicity.
Anthracycline cardiotoxicity
TLDR
Interactions of anthracyclines with comorbidities or unfavorable lifestyle choices were identified as important cofactors of the lifetime risk of cardiotoxicity and as possible targets of preventative strategies.
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
TLDR
Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines, should future investigation confirm its efficacy and advantageous safety profile, could potentially replace older generation topoisomerase poisons in the treatment of AML and other malignant conditions.
...
...

References

SHOWING 1-10 OF 434 REFERENCES
Cardiac toxicity of antineoplastic anthracyclines.
TLDR
No major improvement in therapeutic index has been obtained in anthracyclines synthesized and screened, but a possible exception might be represented by the new disaccharidic derivatives, which have provided promising results in preclinical studies.
The anthracyclines: will we ever find a better doxorubicin?
  • R. Weiss
  • Biology, Chemistry
    Seminars in oncology
  • 1992
TLDR
Current studies are evaluating increased doses of epirubicin to improve anthracycline cytotoxicity, while limiting cardiotoxicity, but at present DOX still reigns in this drug class as the one having the most proven cancerocidal effect.
Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road.
TLDR
This review will present recent strategies in anthracycline design and assess their potential therapeutic merits, including cytoplasmic or nuclear sites.
Recent developments in the field of antitumour anthracyclines.
  • C. Monneret
  • Biology, Chemistry
    European journal of medicinal chemistry
  • 2001
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
  • G. MinottiG. CairoE. Monti
  • Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 1999
TLDR
The present review applies a multisided approach to the critical evaluation of various hypotheses proposed over the last decade for the role of iron in anthracycline‐induced cardiotoxicity to build a unifying pattern that would both account for hitherto unexplained experimental observations and help design novel and more rational strategies toward a much‐needed improvement in the therapeutic index of anthRacyclines.
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines.
TLDR
The evidence that a novel disaccharide analog, endowed with an improved preclinical activity over doxorubicin, was also more effective as an inducer of apoptosis provided additional insights to better understand the cellular processes that confer sensitivity to anthracyclines.
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
TLDR
Data indicate that bolus administration, rather than continuous infusion, appears to be an important risk factor for anthracycline-induced cardiomyopathy, thus implying that this type of toxicity is maximum concentration-dependent.
Anthracyclines: selected new developments.
TLDR
This review will focus on areas of the anthracycline field including synthesis of new analogues, new strategies of synthesis and recent developments in the area of drug delivery.
Idarubicin: a brief overview on pharmacology and clinical use.
TLDR
IDA has become an important drug in the treatment of acute leukemias and its potency in lymphomas, plasmocytomas and other solid tumors such as breast cancer is currently under investigation in several clinical studies.
...
...